Gapping down
Other news:
- ALDX -38.3% (announced top-line results from Phase 3 TRANQUILITY trial in dry eye disease; primary endpoint of ocular redness was not met)
- AQST -28.1% (receives notification from FDA that it will not be ready to take action by December 23, 2021 for the Company's NDA for Libervant Buccal Film)
- DBVT -19.3% (announced plans to initiate new Phase 3 clinical study for modified Viaskin Peanut patch and to withdraw the MAA for Viaskin Peanut in Europe)
- CTMX -17.2% (announced preliminary results from Phase 2 expansion study of CX-2029 in patients with sqNSCLC or HNSCC)
- MNMD -6.7% (provides status update on IND for phase 2b Trial of LSD for the treatment of generalized anxiety disorder)
- ACAD -5.5% (announced plans to resubmit sNDA for NUPLAZID),
Analyst comments:
- VIR -4% (downgraded to Underperform from Neutral at Robert W. Baird)
- URI -1.2% (downgraded to Neutral from Outperform at Robert W. Baird),